source
- Revolution Medicines secures FDA approval for Rasonque, a RAS inhibitor targeting advanced pancreatic cancerRevolution Medicines announced FDA approval of its RAS inhibitor Rasonque for patients with advanced pancreatic cancer, marking a milestone for the company. The approval is seen as a breakthrough…
- ALS research pivots to biology-driven biomarkers to capture disease heterogeneityALS drug development is moving beyond traditional measures such as survival time and the ALS Functional Rating Scale. Researchers are now adding biology‑focused approaches that aim to reflect the f…